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Patient satisfactionTypically, botulinum toxin injections for blepharospasm or cervical dystonia (CD) are administered at approxi-
mately 3-month intervals, reﬂecting concerns that shorter intervals might increase the risk of adverse
events (AEs) and development of neutralizing antibodies. These post-hoc analyses investigated ﬂexible
incobotulinumtoxinA (Xeomin®) injection intervals (6–20 weeks) in patients with blepharospasm or CD.
Patients received up to 6 injections at intervals≥6 weeks, as determined by physician assessment upon patient
request. The blepharospasm study permitted ﬂexible doses (≤50 U/eye). The CD study employed ﬁxed dosing
using incobotulinumtoxinA 120 U, 240 U, or placebo for the ﬁrst treatment followed by subsequent random-
ization to 120 U or 240 U for the extension period. Standard safety assessments were performed. Intervals
b12 weeks were employed in 207 of 461 (44.9%) treatment cycles for blepharospasm and in 369 of 821
(44.9%) treatment cycles for CD. The most frequent AEs were eyelid ptosis and dry eyes in patients treated for
blepharospasm, and dysphagia and neck pain in patients with CD. AE frequency and severity were similar for
intervals b12 weeks and ≥12 weeks in both studies. In conclusion, repeated incobotulinumtoxinA injections
employing ﬂexible intervals (6–20 weeks) per patients' needs werewell tolerated. No additional safety concerns
were observed with b12-week intervals compared with ≥12-week intervals.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Repeated intramuscular injections of botulinum toxin are the rec-
ommended ﬁrst-line treatment for focal dystonias, including blepharo-
spasm and cervical dystonia (CD) [1–3].
IncobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals GmbH,
Frankfurt, Germany; also known as NT 201), a puriﬁed botulinum
toxin type A formulation free from complexing (or accessory) proteins
[4], has been shown to be effective and well tolerated in pivotal Phase
III clinical studies in blepharospasm [5,6] and CD [7,8]. In the CD study,
subgroup analyses conﬁrmed that incobotulinumtoxinA efﬁcacy and
tolerability were similar for patients who were naïve to botulinum
toxin treatment and those who had previously received treatment
with onabotulinumtoxinA (Botox®, Allergan Inc., Irvine, CA, USA) [9].
The effectiveness of incobotulinumtoxinA in treating CD has beenr of Arizona, 9590 E. Ironwood
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. This is an open access article underfurther conﬁrmed in a prospective, long-term, open-label Phase IV
study [10]. Further pivotal, randomized, parallel-group head-to-head
studies have demonstrated that, at a clinical conversion 1 U:1 U dose
ratio, incobotulinumtoxinA and onabotulinumtoxinA showed compara-
ble efﬁcacy and adverse-event (AE) proﬁles when used to treat blepha-
rospasm [11,12] or CD [13].
Current product labeling of botulinum toxin type A formulations
licensed for the treatment of blepharospasm and CD in the USA and
Europe recommends injection intervals of at least 3 months or
12 weeks [14–18], with the exception of European labeling for
incobotulinumtoxinA, which recommends aminimum treatment inter-
val of 12 weeks for blepharospasm and 10 weeks for CD [19].
The recommendedminimum interval of 12 weeks is largely based on
a retrospective chart review of patients with CDwho received treatment
with the early botulinum toxin formulation of onabotulinumtoxinA [20].
However, for many patients with CD, the duration of botulinum toxin
treatment effect is less than 12 weeks [21]. Moreover, a recent patient
survey revealed that many patients who receive botulinum toxin type
A for the treatment of CD would prefer more frequent injections than
the currently recommended 12-week inter-dose interval permits [22].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
117V.G.H. Evidente et al. / Journal of the Neurological Sciences 346 (2014) 116–120A survey of patients with spasticity resulted in similar ﬁndings [23].
However, the tolerability of ﬂexible botulinum toxin dosing regimens
with shorter or longer treatment intervals than the 12-week standard
of care has not been evaluated in prospective clinical studies. Here, we
report ﬁndings from exploratory post-hoc analyses evaluating the safety
of ﬂexible incobotulinumtoxinA injection intervals of 6–20 weeks in the
treatment of blepharospasm and CD from the only two prospective,
randomized, double-blind, multicenter studies and their extension
phases.2. Materials and methods
2.1. Study design
The designs of the studies in blepharospasm and CD have been
described in detail [5–8]. Brieﬂy, the main periods of both studies
comprised a randomized, placebo-controlled, double-blind period
of up to 20 weeks' duration followed by a long-term extension
period.
In the blepharospasm study, patients received injections of
incobotulinumtoxinA (≤50 U per eye) at ﬂexible intervals ≥6 weeks
according to clinical need indicated by a Jankovic Rating Scale (JRS)
Severity subscore N2. Over the entire study, i.e. the main and extension
periods, patients could receive up to six incobotulinumtoxinA injections
[5,6].
The CD study was designed with ﬂexible injection intervals using
ﬁxed doses. In the main period, patients were randomized to receive
placebo, incobotulinumtoxinA 120 U or 240 U. In the double-blind
extension period, all patients were re-randomized to either
incobotulinumtoxinA 120 U or 240 U, independently of their treatment
allocation in the main period. Injection intervals were ﬂexible, with
minimum intervals of ≥8 weeks after the main period injection and
≥6-week intervals for the extension period. Clinical need for
re-injection was deﬁned as a Toronto Western Spasmodic Torticollis
Rating Scale (TWSTRS)-Total score ≥20. In total, patients could receive
up to six incobotulinumtoxinA injections [7,8].2.2. Patients
Detailed inclusion and exclusion criteria for each study have been
described previously. Brieﬂy, the blepharospasm study enrolled
patients who had previously been treated with onabotulinumtoxinA
(≥2 treatments) and who had a stable therapeutic response directly
prior to study entry [5]. The CD study included both botulinum toxin
type A treatment-experienced and -naïve patients [7].2.3. Safety outcome measures
Standard safety assessments were performed throughout the main
and extension periods of both the blepharospasm and CD studies,
including recording of AEs, with active questioning for the occurrence
of AEs of special interest.
In the blepharospasm study, patients were speciﬁcally asked about
any occurrence of AEs that could indicate local or distant toxin spread,
in particular eyelid drooping, vision problems, dry mouth, swallowing
difﬁculties, speech problems, shortness of breath, respiratory infection,
local weakness, facial weakness, general body weakness, and stomach
or bowel disturbances [5,6].
In the CD study, AEs that could indicate the possible spread of the
toxin, including muscular weakness, dysphagia, and dry mouth, were
recorded. In addition, patients were speciﬁcally assessed for swallowing
difﬁculties at each clinic visit and during telephone contacts between
visits using a 5-point dysphagia rating scale [7,8].2.4. Exploratory post-hoc analyses
The exploratory analyses of both studies included all
incobotulinumtoxinA injections that were administered with injection
intervals of 6–20 weeks during the main and extension periods (an
injection interval that was not a whole number, when counted in
weeks, was allocated to the next higherweek). Injections given at inter-
vals b6 weeks or N20 weeks were excluded. Injection cycle 1 denoted
the interval between a patient's ﬁrst and second incobotulinumtoxinA
injection. The last injection cycle was deﬁned as the interval between
the last incobotulinumtoxinA injection and the study termination visit
(up to 20 weeks after the last injection).
For both studies, the frequency of injection interval length (in
weeks) was analyzed by injection cycle. The occurrence of AEs was
summarized for intervals of different lengths and analyzed for all injec-
tion cycles combined.
3. Results
3.1. Patients
In the blepharospasm study, 102/109 patients (93.6%) completed
the main period and entered the extension period; 82/102 patients
(80.4%) completed the extension period. Baseline demographics have
been described [5,6]. In the CD study, 214/233 patients (91.8%) com-
pleted the main period and entered the extension period; 169/214
patients (79.0%) completed the extension period. Baseline demo-
graphics have been published [7,8].
3.2. Frequency of injection intervals
In the blepharospasm study, 461 incobotulinumtoxinA injection
sessions were administered at intervals of 6–20 weeks during the
main and extension periods and were included in this analysis
(Table 1). Of these, 44.9% of treatments were administered with injec-
tion intervals b12 weeks and 55.1% were administered with intervals
≥12 weeks (Fig. 1a). For injection cycle 1, the injection interval was
b12 weeks for 59.8% of treatments and b10 weeks for 48.5% (Table 1).
Overall, 26.5% of injections were administered with intervals
b10 weeks.
In the CD study, 821 incobotulinumtoxinA injection sessions were
administered at intervals of 6–20 weeks during themain and extension
period and included in the exploratory analysis (Table 1). As in the
blepharospasm study, 44.9% of treatments overall were administered
with intervals b12 weeks and 55.1% with intervals ≥12 weeks
(Fig. 1b). For injection cycle 1, the injection interval was b12 weeks
for 59.9% of treatments and b10 weeks for 47.8% (Table 1). Throughout
the study, 29.5% of treatments were administered at intervals
b10 weeks.
3.3. Frequency of adverse events by injection interval
In the blepharospasm study, the overall frequency of AEswas similar
for all incobotulinumtoxinA injection interval groups (Table 2). There
were no differences in the frequency of AEs between injection intervals
b12 weeks and≥12 weeks for each injection cycle, even for intervals as
short as 6–7 weeks. Regardless of the length of the injection interval,
the most frequently reported AEs were dry eyes, ptosis, and dry
mouth (Table 2).
Similarly, in the CD study, the overall frequency of AEs for each injec-
tion cyclewas comparable between treatments at incobotulinumtoxinA
injection intervals b12 weeks and ≥12 weeks, even for the shortest
treatment intervals (Table 2). Dysphagia, muscular weakness, neck
pain, and injection-site pain were the most frequently reported AEs,
irrespective of the length of the injection interval (Table 2).
Table 1
Frequency of injection interval length for each injection cycle among patients in the blepharospasm and cervical dystonia studies.
Injection interval (weeks) Frequency of injection interval length for each injection cycle (% of treatments)
Injection cycle 1 Injection cycle 2 Injection cycle 3 Injection cycle 4 Injection cycle 5 Injection cycle 6 Cycles 1–6 combined
Blepharospasm study
Number of treatments n = 97 n = 90 n = 85 n = 83 n = 71 n = 35 n = 461
6–7 30.9 16.7 8.2 8.4 5.6 8.6 14.3
8–9 17.5 6.7 15.3 8.4 12.7 11.4 12.1
10–11 11.3 22.2 14.1 20.5 19.7 31.4 18.4
12–13 23.7 26.7 36.5 34.9 35.2 17.1 29.9
14–15 8.2 16.7 14.1 18.1 11.3 17.1 13.9
16–17 3.1 7.8 7.1 3.6 7.0 5.7 5.6
18–20 5.2 3.3 4.7 6.0 8.5 8.6 5.6
Cervical dystonia study
Number of treatments n = 207 n = 170 n = 145 n = 140 n = 106 n = 53 n = 821
6–7 5.3 12.4 6.2 9.3 8.5 3.8 7.9
8–9 42.5 16.5 15.9 14.3 13.2 7.5 21.6
10–11 12.1 16.5 13.1 15.7 25.5 11.3 15.5
12–13 19.3 20.6 25.5 22.9 33.0 32.1 23.9
14–15 10.1 15.3 17.2 17.1 5.7 26.4 14.1
16–17 4.3 10.0 11.0 12.9 7.5 5.7 8.6
18–20 6.3 8.8 11.0 7.9 6.6 13.2 8.4
All incobotulinumtoxinA injections (main period and extension period) with treatment intervals of 6–20 weekswere included in the analyses. Any injection interval that was not a whole
number, when counted in weeks, was allocated to the next higher week.
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The current standard of care for patients who receive botulinum
toxin injections for blepharospasm or CD is treatment intervals of no
less than 3 months [14–19,24]. However, in clinical practice many
patients with CD experience a duration of botulinum toxin treatment
effect of b12 weeks [21]. A strict 3-monthly injection interval regimen
maymean that many patients experience a re-emergence of symptoms
before a new injection is administered, resulting in a decrease in treat-
ment satisfaction toward the end of the injection cycle among patients
treatedwith onabotulinumtoxinAor abobotulinumtoxinA [22]. A recent
survey among patients who received botulinum toxin injections for the
treatment of CD showed that more ﬂexible dosing regimens were
considered a desirable aspect of treatment; 45% of patients indicated a
preference for treatment intervals ≤10 weeks [22]. According to the
survey, the main rationale for setting patients' treatment intervals was
a perceived increased risk of side effects and immunoresistance with
shorter intervals [22]. However, clinical data evaluating a potential
effect of botulinum toxin injection intervals on tolerability are lacking.
We have performed exploratory analyses assessing AEs at different
injection interval lengths in two clinical studies of incobotulinumtoxinA
in patients with blepharospasm or CD. In both studies, 12–13 weeks
was the most frequent injection interval length. However, many injec-
tions were administered with shorter or longer intervals, and nearly
half of treatments were administered with intervals b12 weeks.0
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Fig. 1. Frequency of injection interval length for all injection cycles among patients in a) the ble
(main period and extension period) with treatment intervals of 6–20 weeks were included in t
was allocated to the next higher week.Patients had to approach their clinic when they felt they required a
new injection and a clinical need for re-injection then had to be
conﬁrmed by the treating physician using a clinical rating scale (JRS in
the blepharospasm study; TWSTRS in the CD study). Hence, the injec-
tion intervals in these studies reﬂect both patient preferences and
clinical need. Importantly, in both studies there was no apparent trend
for an increased frequency of AEs with shorter injection intervals and
no difference between AE rates for incobotulinumtoxinA injections
given at b12-week intervals versus ≥12-week intervals, even for
incobotulinumtoxinA injections given at intervals as short as 6–
7 weeks.
The recommendation of a 3-month injection cycle is largely based
on a retrospective patient chart review byGreene et al. [20]. The authors
compared the treatment regimens of eight patients with CD who had
become unresponsive to botulinum toxin type A with a cohort of 32
patients who remained responsive and found that patients who lost
responsiveness had received treatment with signiﬁcantly shorter inter-
vals and higher dosing, and had had more booster injections than
patients who remained responsive [20]. However, the patients included
in the review had started botulinum toxin therapy in 1988 and were
injected with an old formulation of onabotulinumtoxinA. This formula-
tion has subsequently been shown to bemuchmore immunogenic than
the current onabotulinumtoxinA formulation, probably owing to a
higher protein load and greater inactive neurotoxin content [25].
Hence, it is unclear if the ﬁndings of Greene et al. can be applied to theb)
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pharospasm study and b) the cervical dystonia study. All incobotulinumtoxinA injections
he analyses. Any injection interval that was not a whole number, when counted in weeks,
Table 2
Frequency of adverse events by injection interval class summarized for all incobotulinumtoxinA treatments in the blepharospasm and cervical dystonia studies.
Frequency of adverse event (%) Injection interval (weeks)
6–7 8–9 10–11 12–13 14–15 16–17 18–20
Blepharospasm study
Number of injections n = 66 n = 56 n = 85 n = 138 n = 64 n = 26 n = 26
Dry eye 4.5 7.1 8.2 5.8 7.8 7.7 7.7
Eyelid ptosis 16.7 3.6 10.6 8.0 17.2 7.7 15.4
Dry mouth 6.1 1.8 3.5 2.9 3.1 3.8 3.8
Cervical dystonia study
Number of injections n = 65 n = 177 n = 127 n = 196 n = 116 n = 71 n = 69
Dysphagia 3.1 5.6 8.7 6.1 7.8 8.5 10.1
Muscular weakness 1.5 2.8 3.1 2.6 2.6 7.0 0
Neck pain 3.1 4.5 4.7 3.6 4.3 5.6 7.2
Injection-site pain 1.5 5.6 3.1 2.6 2.6 2.8 1.4
All incobotulinumtoxinA injections (main period and extension period) with treatment intervals of 6–20 weekswere included in the analyses. Any injection interval that was not a whole
number, when counted in weeks, was allocated to the next higher week.
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incobotulinumtoxinA, which is free from complexing (accessory)
proteins. In the studies included in these analyses, no patients newly
developed neutralizing antibodies (as measured using the mouse
hemidiaphragm assay), even in patients with the shortest injection
intervals [5–8]. This is consistent with other recent studies of repeated
incobotulinumtoxinA treatments in CD [10] and spasticity [26,27] and
supports accumulating evidence that incobotulinumtoxinA is associated
with low immunogenicity, at least during the ﬁrst six injection cycles.
More long-term studies with a greater number of injection cycles are
necessary to determine if injection intervals b12 weeks have any inﬂu-
ence on the development of possible immunoresistance.
Accumulating evidence in recent literature suggests that, after
peripheral injection, botulinum toxin acts not only on neuromuscular
junctions butmay have additional effects on the central nervous system
[28,29]. It is currently unclear if these central actions are clinically
relevant for patients who receive botulinum toxin treatment for CD or
blepharospasm and if they are affected by treatment intervals.
In conclusion, exploratory analysis of clinical study data in blepharo-
spasm and CD showed that repeated injections of incobotulinumtoxinA
were well tolerated when administered with ﬂexible injection intervals
of between 6 and 20 weeks according to patients' request and clinical
need. No additional safety concerns and no cumulative effects were
observed when incobotulinumtoxinA was given at short intervals of 6
to b12 weeks compared with longer intervals of ≥12 to 20 weeks.
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